Pyridine is diamagnetic and has a diamagnetic susceptibility of −48.7 × 10−6 cm3·mol−1.The molecular electric dipole moment is 2.2 debyes. 5315-25-3, formula is C6H6BrN, Name is 2-Bromo-6-methylpyridine. TThe standard enthalpy of formation is 100.2 kJ·mol−1 in the liquid phase and 140.4 kJ·mol−1 in the gas phase. Application In Synthesis of 5315-25-3.
Duan, Zhe;Liu, Jingqiu;Niu, Liping;Wang, Jun;Feng, Mingqian;Chen, Hua;Luo, Cheng research published 《 Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening》, the research content is summarized as follows. IDH1 mutations are early events in the development of IDH-mutant gliomas and leukemias and are associated with various regulation of mol. process. Mutations of active site in IDH1 could lead to high levels of 2-HG and the suppression of cellular differentiation, while these changes can be reversed by mol. inhibitors target mutant IDH1. Here, through inhouse developed enzymic assay-based high throughput screening platform, we discovered DC_H31 as a novel IDH1-R132H/C inhibitor, with the IC50 value of 0.41 μmol/L and 2.7 μmol/L resp. In addition, saturable SPR binding assay indicated that DC_H31 bound to IDH1-R132H/C due to specific interaction. Further computational docking studies and structure-activity relationship (SAR) suggest that DC_H31 could occupy the allosteric pocket between the two monomers of IDH1-R132H homodimer, which accounts for its inhibitory ability. And it is possible to conclude that DC_H31 acts via an allosteric mechanism of inhibition. At the cellular level, DC_H31 could inhibit cell proliferation, promote cell differentiation and reduce the production of 2-HG with a dose-dependent manner in HT1080 cells. Taken together, DC_H31 is a potent selective inhibitor of IDH1-R132H/C both in vitro and in vivo, which can promote the development of more potent pan-inhibitors against IDH1-R132H/C through further structural decoration and provide a new insight for the pharmacol. treatment of gliomas.
Application In Synthesis of 5315-25-3, 2-Bromo-6-methylpyridine (2BMPy) is a bromopyridine derivative. It is formed when 2-chloro-6-methylpyridine is heated with bromotrimethylsilane. Its synthesis from various methods have been reported.
2-Bromo-6-methylpyridine is a building block in the preparation of nitrogen containing heterocyclic compounds.
2-Bromo-6-methylpyridine is an organic compound that belongs to the group of pyridinium halides. It is soluble in common solvents such as water, ethanol, and acetone. 2BMPy has been shown to act as a glutamate receptor antagonist and has been used in the study of glutamate receptors, including their subtypes. This chemical has also been shown to have antioxidant properties and can be used in the prevention of atherosclerosis., 5315-25-3.